et al., Int. J. Antimicrobial Agents, doi:10.1016/j.ijantimicag.2020.106144 (Peer Reviewed)
Retrospective 8,075 hospitalized patients, 4,542 low-dose HC
Q, 3,533 control. 35% lower mortality for HC
Q (17.7% vs. 27.1%), adjusted HR 0.68 [0.62–0.76]. Low-dose HC
Q monotherapy was independently associated with lower mortality in hospitalized patients.
Patients exposed to others therapies (TCZ, AZ, LPV/RTV) were excluded.
Statistical analysis was performed by an independent group. Calendar time of prescription and immortal time bias was taken into account. Corticosteroids prescriptions was low in both groups.